Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665573 · ClinicalTrials.gov registry record · Early Phase 1
Cannabinoid Augmentation of Fear Response in Humans
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
NCT01665573 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 31 participants.
The verdict
NCT01665573, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this double blind, randomized, controlled, proof-of-concept study is to test the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On three days over not more than two weeks, subjects will be trained to associate cues with two different stimuli, then this association will be extinguished. Cannabinoid receptor stimulation will be accomplished indirectly by harnessing the brain's capacity to endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845. Some details of this study have not been disclosed to preserve the study design.
Interventions
- DRUG Placebo
- DRUG PF-04457845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2012-07-17 |
| Est. Completion | 2015-10-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01665573
The ClinicalTrials.gov registry entry for NCT01665573 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01665573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01665573 about?
NCT01665573 is a clinical study titled "Cannabinoid Augmentation of Fear Response in Humans". The purpose of this double blind, randomized, controlled, proof-of-concept study is to test the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On three days over not more than two weeks, subjects will be trained to associate cues with two different stimuli, th...
What is the current status of trial NCT01665573?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2012-07-17. Estimated completion is 2015-10-16.
What interventions are being tested in trial NCT01665573?
The interventions under investigation include: Placebo (DRUG), PF-04457845 (DRUG).
Who is sponsoring clinical trial NCT01665573?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.